A computerized clinical decision support tool implemented as a diagnostic stewardship intervention led to an approximate 50% decrease in urine culture testing for patients with a urinary catheter, ...

A new study investigates the role of Krüppel-like factor 2 (KLF2, a protein coding gene involved in a variety of regulatory ...

Ongoing commercial launch of AUCATZYL® on track, with 24 treatment centers fully authorized as of January 10th- National Comprehensive Cancer ...

X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, ...

X4 to receive a €28.5 million upfront payment and up to €226 million in potential regulatory and commercial milestone payments in addition to tiered ...

For patients with relapsed or refractory multiple myeloma, talquetamab plus teclistamab shows response in a high perc ...

Seres Therapeutics, Inc. (Nasdaq: MCRB) (Seres or the Company), a leading live biotherapeutics company, today announced new translational biomarker results for exploratory endpoints from its SER-155 ...

Physiomics said its software was initially developed to help clinicians with chemotherapy dosing decisions, but the results of a Partner study in January 2023 indicated that the software could be ...

Young patients with low-risk, relapsed Hodgkin lymphoma may be able to avoid transplant, data from 3 studies suggest.

An FDA-approved medication called glucarpidase could serve as an antidote to kidney toxicity in patients receiving the chemotherapy drug methotrexate (MTX), according to a new study by investigators ...

Glucarpidase -- a carboxypeptidase enzyme that helps break down and remove methotrexate from the body -- was approved by the ...